Levodopa therapy for Parkinson's disease: Challenges and future prospects

Movement Disorders

Volumn 23, Issue SUPPL. 3, 2008, Pages

  Olanow, C Warren ^a   Lees, Andrew ^b   Obeso, Jose ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; LEVODOPA; PLACEBO;

BASAL GANGLION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DYSKINESIA; EDITORIAL; HUMAN; LONGEVITY; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; SYMPTOM; VOMITING;

ACTIVITIES OF DAILY LIVING; ANTIPARKINSON AGENTS; HUMANS; HYPOTENSION; LEVODOPA; NAUSEA; PARKINSON DISEASE; QUALITY OF LIFE; VOMITING;

EID: 53149106644     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22048     Document Type: Editorial

References (6)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
2. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
3. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N EngI J Med 2004;351:2498-2508.
4. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation in the treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
5. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Infusion of levodopa methyl ester in patients with advanced PD: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
6. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.